The FDA now says Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss
Summary
Recent medical studies indicate that popular diabetes and weight-loss drugs known as GLP-1 medications may carry an increased danger of vision loss. Specifically, researchers have linked these treatments to a rare eye condition that restricts blood flow to the optic nerve.
Several medical studies have found that people taking GLP-1 medications have an elevated risk for nonarteritic anterior ischemic optic neuropathy, or NAION.
Source: Read the full story at MarketWatch.com - Top Stories
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.